Which display strategies boost xphozah sales?

What display strategies lift sales for Xphozah?

Display tactics that keep Xphozah visible at the pharmacy shelf or in digital ads right when patients pick up their prescriptions raise awareness and fill rates. Visibility at the point of care matters because Xphozah treats hyperphosphatemia in dialysis patients, a group that returns regularly for refills.

How do shelf-talkers and counter cards affect sales?

Shelf-talkers and counter cards draw immediate attention to Xphozah among competing binders. They list quick facts about lower pill burden and less GI upset, helping patients and pharmacists choose it over legacy options such as sevelamer or calcium acetate.

Does in-pharmacy digital signage improve uptake?

In-pharmacy digital signage cycling through Xphozah clinical highlights and insurance coverage messages reaches patients who already have insurance pre-authorization. Coverage messages reduce time to fill and raises fill rates, especially when paired with patient assistance programs.

What role does co-branded display materials play?

Co-branded materials supplied by the manufacturer or distributor help store owners install consistent signage that meets FDA fair balance requirements. Consistent messaging avoids regulatory issues and keeps the drug name and key messages front-of-mind.

When does display material timing coincide with insurance coverage changes?

Display campaigns timed around January formulary changes or Medicare open enrollment periods show higher impact. Coverage status shifts from Tier 4 to Tier 2 or inclusion on preferred lists of dialysis organizations drive sudden spikes in demand, and display reminders help turn coverage into actual fills.

What price points do patients report seeing?

Patients report seeing Xphozah prices ranging from $1,000 to $1,800 per month before discounts or insurance. With patient assistance programs and co-pay cards, many report net costs zero to $10 per month.